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Resistance to radiation is considered to be an important
reason for local failure after radiotherapy and tumor
recurrence. However, the exact mechanisms of tumor
resistance remain poorly understood. Current investigations
of microRNAs as potential diagnostic and therapeutic tools
for cancer treatment have shown promising results. With
respect to radiotherapy resistance and response, there is now
emerging evidence that microRNAs modulate key cellular
pathways that mediate response to radiation. These data
suggest that microRNAs might have significant potential as
targets for the development of new therapeutic strategies to
overcome radioresistance in cancer. This review summarizes
the current literature pertinent to the influence of micro-
RNAs in the response to radiotherapy for cancer treatment,
with an emphasis on microRNAs as novel diagnostic and
prognostic markers, as well as their potential to alter
radiosensitivity.  2016 by Radiation Research Society
INTRODUCTION
Radiation therapy induces a complex cellular response
when treating cancer cells and leads to changes in the
expression of numerous genes involved in key cellular
processes such as cell signaling, proliferation and damage
response (1, 2). Cellular damage after radiotherapy occurs
either directly by disruption of DNA integrity or indirectly
by free radicals and reactive oxygen species that cause DNA
double-strand breaks (DSBs) (2–4). As a result, complex
signaling pathways are activated and DNA damage
response is triggered. Cell death occurs from a failure to
repair radiation-induced damage (1, 5).
Several factors have been shown to influence response to
radiation, including tumor origin, vascular supply/extent of
hypoxia, cell-cycle phase and the repopulation potential of
surviving cells (6, 7). However, the main factor influencing
response to radiotherapy seems to be the intrinsic
radioresistance of tumor cells. Despite increasing knowl-
edge about the effects of radiation on biochemical
pathways, the exact mechanisms of intrinsic radioresistance
remain unclear. To date, it has been reported that a number
of key cellular features appear to play a role in the
development of intrinsic radioresistance, including overex-
pression of DNA repair proteins (8), modifications of
signaling pathways (9), angiogenesis (10) and the presence
of cancer stem cells (11).
Resistance to radiotherapy remains a serious obstacle to
successful cancer therapy and directly impacts clinical
outcomes (12). Unfortunately, there are currently no reliable
clinical or molecular markers available that help estimate or
predict response (13). In this context, microRNAs (miR-
NAs), a class of regulatory molecules that play an essential
role in various physiological and pathological processes
such as cancer development, might be promising candidates
(14, 15). miRNAs are considered to be highly specific
biomarkers with potential for clinical applications, and their
expression has been shown to correlate with tumor
occurrence, development, clinical prognosis and therapeutic
efficacy (3, 14). Beyond their use as diagnostic or
prognostic biomarkers, the manipulation of miRNAs may
offer new opportunities in the treatment of cancer . Recent
studies have shown that miRNAs play an important role in
radiation-induced gene expression, cell-signaling events and
regulation of damage-response pathways (16, 17). Most
interestingly, miRNAs have been shown to modulate
radiosensitivity (1, 5). Therefore, miRNAs might be
promising candidates for the assessment and monitoring
of radiosensitivity of tumors, as well as modulation of
response to radiation treatment (18).
METHODS
A PubMed search was performed using combinations of the
following keywords: miRNA, microRNA, biomarker, radiotherapy,
radioresistance and radiosensitivity. Articles that met the criteria were
identified (number of articles found are inticated in parentheses):
1 Address for correspondence: Department of Surgery, Flinders
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miRNA and radiotherapy (324); microRNA and radiotherapy (341);
miRNA and radioresistance (76); microRNA and radioresistance (70);
miRNA and radiosensitivity (197); microRNA and radiosensitivity
(203); radiation and miRNA and biomarker (117); radiation and
microRNA and biomarker (123); and circulating and miRNA and
radiation (19). Relevance was further determined by screening the
abstracts and text of the entire published article, as necessary.
Reference lists from relevant articles were also searched for additional
literature. Data were extracted from the article or, if only available in
the abstract, from there. This method was applied until the beginning
of June 2015.
A narrative review of relevant literature was conducted to identify
and summarize evidence that miRNAs might be useful as biomarkers
to predict and monitor response to radiotherapy, and also to determine
the potential for manipulation of miRNAs to modulate radiotherapy
response. The underlying mechanisms of action by which miRNAs
might affect sensitivity to radiotherapy were also reviewed.
miRNAS AS POTENTIAL NEW CLINICAL MARKERS
FOR DIAGNOSIS, PROGNOSIS AND TREATMENT
miRNAs have potential for use as clinically relevant
biomarkers of response to radiotherapy, and also to
modulate radiotherapy response.
MiRNAs as Predictors of Response to Radiotherapy
Given the variety of patient responses to radiation
treatment, the ability to predict response versus non-
response would allow treatment to be individualized,
thereby helping patients avoid unnecessary risks of toxicity
and side effects if they are unlikely to benefit from
radiotherapy (19, 20). To distinguish between responders
versus non-responders using miRNA profiling methods,
distinct differences in miRNA expression profiles of tumors
for each patient group must be present. Unfortunately, most
clinical and experimental studies investigating miRNAs and
their correlation to treatment response include patients that
have undergone combined chemo-radiotherapy, making it
difficult to identify miRNAs that specifically correlate with
only radiotherapy response. However, in a limited number
of recent studies using cancer cell lines or clinical samples,
it has been reported that miRNAs investigated in the setting
of radiotherapy alone have shown promising early results
(21).
For example, using samples from patients with non-small
cell lung cancer, Wang et al. demonstrated that 5 miRNAs
were significantly upregulated in radiosensitive tumors (let-
7a; miR-126, -128b, -451, -495) and 7 miRNAs were
downregulated compared to controls (miR-15b; -17-5p, -19b,
-21, -22, -106b, -130a) (22). In another study, higher miR-
18a expression levels were observed in tumors from patients
who failed to respond to radiation treatment, compared to
responders (P¼ 0.019) (23).
In the context of head and neck tumors, Qu et al. established
a radiation-resistant nasopharyngeal carcinoma cell line and
reported 8 miRNAs to be differentially expressed compared to
the parental cells (upregulation of let-7g, miR-205; -224;
downregulation of miR-18a; -19b, -24, -93, -103), with the
most significant expression changes between resistant and
sensitive cells seen for miR-205 (24). In another published
study, miR-196a was shown to be the most upregulated
miRNA of 41 differentially expressed miRNAs in squamous
cell carcinoma tumor samples from non-responders compared
to responders (25).
Similar results have been demonstrated in biopsies from
squamous cervical carcinoma, with miR-16-2, -18a, -23a, -30,
-221 and -378 downregulated in samples from radiation-
resistant tumors sampled six months after completion of
radiation treatment, while miR-21 and miR-181a were found
to be upregulated. However, the significance of this study is
limited, since patients underwent concurrent cisplatin chemo-
therapy (12). Table 1 summarizes the published studies that
suggest miRNAs have a potential role as predictors of
radiotherapy response.
MiRNAs to Monitor Response to Radiotherapy
As radiotherapy is usually delivered over several weeks,
early identification of patients who are failing to respond
might provide an opportunity to avoid ineffective treatment
or delays in moving to alternative treatment options. For
‘‘real-time’’ assessment of radiotherapy response using
miRNA profiling methods, miRNA expression should
change in a characteristic manner across the course of
successful radiotherapy treatment. Some recently published
studies using miRNA profiling techniques, including
microarrays, real-time quantitative PCR and next-generation
deep sequencing, have revealed that exposure to radiation
triggers specific changes in miRNA expression (26).
General changes in miRNA expression under radiother-
apy. The majority of published studies have focused on
(benign or malignant) cell lines or cancer tissue biopsies, and
investigated whether radiation exposure is associated with
characteristic changes to miRNA expression profiles (5, 27–
31). In benign cells, miRNA expression has been shown to be
significantly impacted by ionizing radiation (27, 28). For
example, in endothelial cells, radiation induced upregulation of
five miRNAs (let-7g, miR-16; -20a, -21, -29c) and downreg-
ulation of six (miR-18a; -125a, -127, -148b, -189, -503) (28).
Similar results have been demonstrated in cancer cell
lines. Niemoeller et al. showed that radiation exposure led
to 2–3-fold changes in the expression levels of various
miRNAs, such as let-7i, miR-24-1, miR-151-5p and miR-
1285 in different cancer cell lines (29). Significantly, certain
miRNAs have been identified to consistently show
characteristic changes postirradiation across a range of
different cancers. For example, expression of several
members of the let-7 family, a well-known tumor
suppressor and regulator of the K-Ras oncogene, were
found to be affected by radiation exposure (29, 30, 32–35).
Most members of the let-7 family (except let-7g) have been
found to be downregulated in irradiated fibroblasts (33),
lung cancer cells (30) or colon cancer cells (35). However,
in irradiated glioma and squamous cell carcinoma cell lines
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some members of the let-7 family are upregulated (29, 34).
Another two miRNAs, miR-21 and miR-34, are consistently
upregulated in various benign and malignant cell lines after
irradiation (28, 34, 36–38).
Only two studies have extended the cell-line outcomes to
the clinical setting and investigated miRNA responses in
tissues from patients undergoing radiotherapy. In irradiated
gastric cancer samples, expression of 18 miRNAs were
TABLE 1
miRNAs as Potential Predictors of Response to Radiotherapy
miRNA
Up/downregulation
vs. controla
Correlation with
radioresponse Cancer type Specimen (dose) Targets Ref.
let-7a   Sensitivity Lung cancer Resected lung samples
(60 Gy)
- (22)
let-7g   Resistance Nasopharyngeal
carcinoma
Cell lines (0–6 Gy) - (24)
miR-15b #  Sensitivity Lung cancer Resected lung samples
(60 Gy)
- (22)
miR-17-5p #  Sensitivity Lung cancer Resected lung samples
(60 Gy)
- (22)
miR-18a   Resistance Lung cancer Resected lung samples
(N.A.); cell lines (10
Gy)
- (23)
#  Resistance Nasopharyngeal
carcinoma
Cell lines (0–6 Gy) - (24)
miR-19b #  Sensitivity Lung cancer Resected lung samples
(60 Gy)
- (22)
#  Resistance Nasopharyngeal
carcinoma
Cell lines (0–6 Gy) - (24)
miR-21 #  Sensitivity Lung cancer Resected lung samples
(60 Gy); cell lines (0–8
Gy)
- (22)
miR-22 #  Sensitivity Lung cancer Resected lung samples
(60 Gy)
- (22)
miR-24 #  Resistance Nasopharyngeal
carcinoma
Cell lines (0–6 Gy) - (24)
miR-93 #  Resistance Nasopharyngeal
carcinoma
Cell lines (0–6 Gy) - (24)
miR-103 #  Resistance Nasopharyngeal
carcinoma
Cell lines (0–6 Gy) - (24)
miR-106b #  Sensitivity Lung cancer Resected lung samples
(60 Gy)
- (22)
miR-126   Sensitivity Lung cancer Resected lung samples
(60 Gy)
- (22)
miR-128b   Sensitivity Lung cancer Resected lung samples
(60 Gy)
- (22)
miR-130a #  Sensitivity Lung cancer Resected lung samples
(60 Gy)
- (22)
miR-181a   Resistance Cervical carcinoma Biopsies (45 Gy); cell
lines (0–8 Gy)
PRKCDb (12)
miR-196a   Resistance Squamous cell
carcinoma of the
head and neck
Tissue samples ANXA1c (25)
miR-205   Resistance Nasopharyngeal
carcinoma
Cell lines (0–6 Gy) PTENc (24)
miR-224   Resistance Nasopharyngeal
carcinoma
Cell lines (0–6 Gy) - (24)
miR-451   Sensitivity Lung cancer Resected lung samples
(60 Gy)
- (22)
miR-495   Sensitivity Lung cancer Resected lung samples
(60 Gy)
- (22)
Note. PRKCD¼ protein kinase C delta type; ANXA1¼ annexin A1; PTEN¼ phosphatase and tensin homolog deleted on chromosome 10; NA
¼ Not available.
a Up-/downregulation (#) of miRNA compared to respective control.
b Assessment of (potential) targets Targetscan research.
c Assessment of (potential) targets using luciferase assay.
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altered more than 1.5-fold (upregulation of miR-138-1 and
mir-637; downregulation of let-7a, and miR-24-1, -141, -300,
-377, -423-3p, -485-3P, -490-5p, -498, -615-3p, -625, -642,
-657, -659 and -943) compared to nonirradiated samples (39).
In nasopharyngeal carcinoma tissues, qRT-PCR revealed
upregulation of miR-205 after irradiation, and this was
consistent with the authors’ in vitro data, which showed
miR-205 to be upregulated in radioresistant cells (24).
Liquid biopsies: the future of molecular diagnostics.
Recent studies have also detected so-called ‘‘circulating
miRNAs’’ in blood samples. These circulating miRNAs,
which are present in stable forms in the blood stream,
might be detectable as clinical biomarkers (40). Radiation-
induced changes in blood-based miRNA expression
profiles have recently been reported. In the context of
myeloablative fractionated exposures before autologous
or allogenic stem cell transplants, expression levels of 45
miRNAs, including miR-17; -21, -101, -126 and -148b,
have been found to significantly increase compared to
preirradiation control samples in mantle cell lymphoma,
acute myelogenous leukemia and acute lymphoblastic
leukemia (41).
Analysis of miR-21 expression levels in the serum of
breast cancer patients at different treatment time points
revealed significantly increased miR-21 levels after radio-
therapy in those individuals who had received chemother-
apy five weeks before radiation treatment (P , 0.001) (42).
In addition, high plasma expression levels of miR-142-3p,
-186-5p, -195-5p, -374b-5p and -574-3p after the second
fraction of radiotherapy were shown to correlate with a
poorer prognosis in patients with head and neck squamous
cell carcinoma (43). However, these patients also underwent
concurrent chemotherapy, which might also influence the
miRNA expression levels. Finally, consistent with obser-
vations made about miR-34 expression in cell lines and
cancer tissue biopsies, serum levels of this miRNA were
shown to be elevated in irradiated mice compared to
nonirradiated controls (44).
Changes in miRNA expression profiles compared to
radiotherapy response. Only one published study ad-
dressed the question of radiation response compared to
changes in miRNA expression profiles. miRNA profiling
of a (radioresistant and radiosensitive) esophageal adeno-
carcinoma cell line identified 11 miRNAs with altered
expression levels after irradiation, and miR-31 was
significantly downregulated in the radioresistant cells
(45). miR-31 expression was subsequently analyzed in
endoscopic esophageal cancer biopsies collected before
commencement of neoadjuvant therapy, and increased
miR-31 levels in these biopsies were found in the patients
with a complete pathologic response. However, because
the clinical samples were collected from individuals who
received combined chemo-radiotherapy, the relevance of
these results to the setting of radiotherapy alone is
probably limited.
MiRNAs as Modulators of Response to Radiotherapy
While miRNAs have potential as diagnostic and prog-
nostic markers in the clinical setting, another important
question is whether these molecules provide a new
opportunity for cancer treatment. Theoretically, manipula-
tion of miRNA levels should result in changes in the
expression of genes critical to radiation response, thereby
altering radiation sensitivity. There is now growing
evidence that modulation of miRNA levels by either
enhancing or suppressing the expression of certain miRNAs
affects radioresistance in some human tumors. For example,
in vitro manipulation of levels of members of the let-7
family and miR-21, miR-181a, miR-221 and miR-222 has
been shown to impact response to radiotherapy in head and
neck squamous cell cancers, uveal melanoma, glioma and
neuroblastoma, gastrointestinal tumors (esophageal, gastric,
colorectal and liver), gender-specific tumors (breast,
cervical and prostate cancer), lung cancer, renal cell cancer
and lymphoma (see Table 2 for details on the effects of up-/
downregulation of different miRNAs on radiosensitivity in
in vitro studies). Initial in vivo studies have confirmed the in
vitro findings that the let-7 family, miR-101, miR-145, miR-
181a, miR-185, miR-210 and miR-381 affect radiosensitiv-
ity in melanoma, glioma, cervical cancer, esophageal
cancer, renal cell cancer and hepatoma (Table 3).
MECHANISMS OF ACTION
As miRNAs act by binding to messenger RNA to
regulate their translation, miRNAs are involved in the
regulation of numerous relevant cellular functions, includ-
ing DNA damage response and important signaling
pathways such as the apoptosis pathway. The impact of
miRNAs and targets relevant to radiation response is
summarized in Fig. 1.
MiRNAs Modulating DNA Damage Response
Radiation-induced cell death is at least in part caused by
miRNA-based repression of pathway components of the
damage response, resulting in an impaired ability to detect
DNA damage (1, 21). One of the most relevant mechanisms
of action of radiotherapy is the initiation of DSBs (5).
Consequently, cellular pathways and repair mechanisms
such as homologous recombination and non-homologous
end joining are activated by different ‘‘damage sensors’’
like ATM (ataxia-telangiectasia mutated) that trigger the
DNA repair system (21). Efficient repair can lead to
radioresistance, which frequently prevents successful treat-
ment (6). Several miRNAs appear to modulate and regulate
these DNA repair mechanisms. For example, in cervical
cancer cell lines, upregulation of miR-18a decreases the
ATM level and attenuates efficient DSB repair after
radiotherapy (46). Two further examples of interaction
between miRNAs and the DSB repair machinery by ATM
modulation are miR-101 and miR-421. These miRNAs have
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TABLE 2
Effect of Up-/Downregulation of Different miRNAs on Radiosensitivity in In Vitro Studies
Cancer type and subtype MiRNA Regulation
Correlation
with response Dose Possible targets Refs.
Head and neck tumors
Squamous cell carcinoma miR-196a   Resistance 0–2 Gy ANXA1 (25)
Oral squamous cell carcinoma miR-125b   Sensitivity 0–8 Gy ICAM-2 (66)
Nasopharyngeal carcinoma miR-185-3p   Sensitivity 6 Gy WNT2B (71)
miR-205   Resistance 10 Gy PTEN (24)
miR-324-3p   Sensitivity 60 Gy WNT2B (72)
Uveal melanoma let-7b   Sensitivity 0–9 Gy Cyclin D1 (73)
Glioma miR-7   Sensitivity 2–8 Gy EGFR-PI3K-Akt (49)
miR-101   Sensitivity 2–8 Gy DNA-PKcs, ATM (47)
miR-181a   Sensitivity 0–35 Gy Bcl-2 (74)
miR-221;
miR-222
#  Sensitivity 2–6 Gy PTEN (57)
Neuroblastoma miR-421   Sensitivity 0–10 Gy ATM (48)
Gastrointestinal tumors
Esophageal miR-21 #  Sensitivity 0–8 Gy PTEN (PI3K-Akt) (60)
miR-22   Sensitivity 0–10 Gy - (75)
miR-31   Sensitivity 2 Gy DNA repair genes (45)
miR-381   Sensitivity 0–8 Gy CTNNB1, LEF1, CDK1,
XIAP, CXCR4
(76)
Gastric miR-221;
miR-222
#  Sensitivity 0–6 Gy PTEN (p-Akt) (58)
miR-451   Sensitivity 0–4 Gy MIF (77)
Colorectal miR-100   Sensitivity 0–8 Gy Apoptosis-related proteins (55)
miR-124   Sensitivity 0–8 Gy PRRX1 (78)
miR-221 #  Sensitivity 0–8 Gy PTEN (54)
miR-451   Sensitivity 0–4 Gy MIF (77)
Hepatoma miR-210 #  Sensitivity 8 Gy AIFM3 (79)
Gender-specific tumors
Breast miR-7   Sensitivity 2–8 Gy EGFR-PI3K-Akt (49)
miR-15   Sensitivity G2 checkpoints (80)
miR-200c   Sensitivity 0-8 Gy TBK1, autophagy (53, 81)
miR-221;
miR-222
#  Sensitivity 2-6 Gy PTEN (57)
Cervical miR-18a   Sensitivity - ATM (46)
miR-145   Sensitivity 0–8 Gy HLTF (82)
miR-181a   Resistance 0–8 Gy PRKCD (12)
Prostate miR-521   Sensitivity 0–6 Gy CSA, MnSOD (37)
Other types
Lung let-7   Sensitivity 2–6 Gy let-60/RAS, DDR (30)
let-7a 0–8 Gy K-Ras (61)
miR-7   Sensitivity 2–8 Gy EGFR-PI3K-Akt (49)
miR-9   Sensitivity 2 Gy NF-jB1 (70)
miR-18a #  Sensitivity 0–10 Gy - (23)
miR-21 #  Sensitivity 0–8 Gy PTEN (59, 64)
miR-34b   Sensitivity 4–12 Gy - (83)
miR-101   Sensitivity 2–8 Gy DNA-PKcs, ATM (47)
miR-126   Sensitivity 0–8 Gy PI3K-Akt (22)
miR-221;
miR-222
#  Sensitivity 2–6 Gy PTEN (57)
miR-449a   Sensitivity 10 Gy - (84)
miR-1323   Resistance - PRKCD (85)
Renal cell miR-185   Sensitivity 4 Gy ATR (86)
Non-Hodgkin lymphoma miR-148b   Sensitivity 2 Gy - (67)
Mantle cell lymphoma miR-17-92   Resistance 0–4 Gy PTEN (87)
Note. ANXA1¼ annexin A1; ICAM-2¼ intercellular adhesion molecule-2; PTEN¼ phosphatase and tensin homolog deleted on chromosome
10; MIF¼macrophage migration inhibitory factor; DNA-PKcs¼DNA-dependent protein kinase catalytic subunit; ATM¼ ataxia-telangiectasia
mutated; DDR¼DNA damage response. PRKCD¼ protein kinase C delta type. TBK1¼ TANK-binding kinase 1; CSA¼Cockayne syndrome
protein A, NF-jB1 ¼ nuclear factor kappa-light-chain-enhancer of activated B cells; MnSOD ¼ manganese superoxide dismutase; HLTF ¼
helicase-like transcription factor; AIFM3¼ apoptosis-inducing factor mitochondrion-associated 3; ATR¼ ataxia telangiectasia and Rad3-related
protein.
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been shown to influence ATM expression, and ectopic
expression/overexpression enhances radiosensitivity in neu-
roblastoma cell lines (miR-421) (47, 48). Other miRNAs,
such as miR-7, miR-101 and miR-182, have been shown to
target transcripts of DSB repair genes such as BRCA1
(breast cancer 1) and DNA-dependent protein kinase
catalytic subunit (DNA-PKcs), respectively, and to radio-
sensitize cells in vitro as well as in xenograft models (47,
49, 50). In a panel of human cancer cells, overexpression of
miR-7, for example, resulted in downregulation of EGFR
and Akt, which was associated with decreased phosphor-
ylation of DNA-PKcs and delayed DNA repair. Conse-
quently, sensitivity to radiotherapy was enhanced (49).
Since EGFR overexpression in solid tumors is associated
with poor prognosis and radiotherapy resistance (49, 51),
the miR-7 axis may represent a novel approach to improve
radioresponse.
However, other miRNAs appear to act predominantly by
different repair pathways of non-DSB DNA damage or
other DNA repair mechanisms. In radiation-resistant
esophageal adenocarcinoma cells overexpression of miR-
31 has been shown to contribute to re-sensitization towards
radiation and altered expression of 13 DNA repair genes
(45). Interestingly, most of the altered genes are involved in
TABLE 3
Effect of Up-/Downregulation of Different miRNAs on Sensitivity to Radiotherapy in In Vivo/Xenograft Studies
MiRNA Regulation
Correlation
with response Animal model Dose Possible targets Refs.
let-7   Sensitivity C. elegans 200/400 Gy let-60/RAS, DDR (30)
let-7b   Sensitivity Uveal melanoma (mice) 12/18 Gy Cyclin D1 (73)
miR-181a   Resistance Cervical (mice) 16 Gy PRKCD (12)
miR-101   Sensitivity Glioma/lung cancer (mice) 10 Gy DNA-PKcs, ATM (47)
miR-145   Sensitivity Cervical (mice) 24 Gy HLTF (82)
miR-381   Sensitivity Esophageal (mice) 5 Gy CTNNB1, LEF1, CDK1,
XIAP, CXCR4
(76)
miR-181a   Resistance Cervical (mice) 16 Gy PRKCD (12)
miR-185   Sensitivity Renal cell (mice) 4 Gy ATR (86)
miR-210 #  Sensitivity Hepatoma (mice) 8 Gy AIFM3 (88)
Note. DDR¼DNA damage response; PRKCD¼ protein kinase C delta type; DNA-PKcs¼DNA-dependent protein kinase catalytic subunit;
ATM¼ ataxia-telangiectasia mutated; HLTF¼ helicase-like transcription factor; ATR¼ ataxia telangiectasia and Rad3-related protein; AIFM3¼
apoptosis-inducing factor mitochondrion-associated 3.
FIG. 1. Impact of miRNAs and targets relevant to radiation response.
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base excision repair, mismatch repair and nucleotide
excision repair pathways, which do not primarily belong
to DSB repair machinery. This is surprising, given that
previously published data from the authors of this study
showed enhanced DSB repair in the same radiation-resistant
cells (45, 52). However, the authors hypothesized that
different DNA repair pathways are critically interlinked
(45). In addition, overexpression of miR-521 sensitized
cells to radiation, while inhibition of miR-521 resulted in
radioresistance. Radiation treatment, as well as downregu-
lation of miR-521, led to increased levels in the DNA repair
protein, Cockayne syndrome protein A (CSA), one of the
predicted target genes of miR-521 (37). Low levels of miR-
200c have been shown to correlate with radioresistance in
breast cancer cells, and overexpression of miR-200c
enhanced radiosensitivity mediated by enhanced radiation-
induced DSBs/apoptosis rates as well as decreased
proliferation rates with TANK-binding kinase 1 (TBK1), a
possible target of miR-200c (53).
MiRNAs Regulating Relevant Cellular Signaling Pathways
In addition to DNA damage response by DSB repair
machinery or non-DSB DNA damage repair mechanisms,
other cell-signaling pathways can impact the cellular
response to radiotherapy. For example, oncogenes and
tumor suppressor genes (54) or apoptotic genes (55) can
affect radiosensitivity. miRNAs play a crucial role in the
regulation of these signaling pathways, as summarized
below.
Oncogenes and tumor suppressor genes. One well-
known tumor suppressor gene is PTEN (phosphatase and
tensin homolog), which acts by negatively regulating the
PKB (protein kinase B, Akt) signaling pathway. This
mechanism is critical for the regulation of the cell cycle, cell
growth and apoptosis (54, 56). In recent years, several
authors have identified numerous miRNAs that can interfere
with the PTEN pathway. For instance, PTEN has been
proven to be a target of miR-221/-222. Knockout of these
miRNAs results in increased PTEN levels, which in turn
lead to suppressed Akt activity and increased apoptosis, and
most importantly, to enhanced radiosensitivity in various
cancer cell lines (57). These results are in agreement with
observations by other authors reporting studies using gastric
(58) and colorectal cancer cell lines (54). Furthermore,
PTEN is a known target of miR-21. Mimics of miR-21
inhibited PTEN expression and enhanced radioresistance in
non-small cell lung cancer cells (59), and inhibition of miR-
21 increased radiosensitivity via PTEN in esophageal cancer
(60). An additional miRNA that potentially targets PTEN is
miR-205. Qu et al. demonstrated that miR-205 increased
radioresistance of nasopharyngeal carcinoma, potentially by
directly targeting PTEN (24).
Another relevant oncogene that is directly regulated by
miRNAs is K-RAS. In the context of radiotherapy
resistance, the lin28-let-7 axis might be of relevance (61).
Ras proteins act as proto-oncogenes, and their 30UTRs
contain let-7 complementary sites, which enable let-7 to act
as a tumor suppressor to regulate Ras expression (31).
Activation of Ras signaling has been shown to increase
survival of tumor cells exposed to radiation (62). Recently,
this regulatory network was analyzed in two studies, and
overexpression of let-7a was shown to suppress K-Ras
expression, which in turn radiosensitized lung carcinoma
cells (61). In line with these results, enhanced radiosensi-
tivity was also achieved by inhibition of lin28, a repressor
of let-7, and this was also followed by decreased K-Ras
expression (61). Similar findings have been observed for
let-7g (63).
Apoptosis. The cellular response to radiation is related to
cell cycle and apoptosis, and a number of miRNAs play key
roles in radiation-induced apoptosis (55). For example,
miR-21 seems to be linked to the apoptotic pathway in lung
cancer cells, and miR-21 contributes to radioresistance by
blocking the pro-apoptotic gene caspase-3. Downregulation
of miR-21 leads to increased radiosensitivity, possibly by
inhibition of cell cycle progress and proliferation (64).
Another miRNA that impacts radioresistance by apoptotic
pathways, miR-125b, appears to be a potential regulator of
intercellular adhesion molecule-2 (ICAM-2), which has
been linked to radiosensitivity in oral squamous cell
carcinoma by interaction with apoptotic signaling pathways
(Akt and caspase-3) (65). Overexpression of miR-125b
results in decreased ICAM-2 levels and proliferation rates
(66). Induction of apoptosis, possibly mediated by inacti-
vation of the PI3K-Akt pathway, can also be a result of
miR-126 overexpression, and lead to enhanced radiosensi-
tivity (22). In an irradiated non-Hodgkin’s lymphoma cell
line, miR-148b has been found to increase radiosensitivity
of cells (67). In this context, radiation-induced apoptosis
through repression of DNA methyltransferase 3b
(DNMT3b) is a possible underlying mechanism (67). In
addition, miR-181a targets another pro-apoptotic gene,
PRKCD (protein kinase C delta type) and contributes to
radioresistance by negative regulation of PRKCD expres-
sion and inhibition of radiation-induced apoptosis in
cervical cancer cell lines (12). Furthermore, miR-196a
overexpression has been shown to increase proliferation
rates and radioresistance in head and neck tumors (25). An
important component in the signaling pathway is the tumor
suppressor annexin A1 (ANXA1), which is a target gene
modulated by miR-196a. Interestingly, miR-196a overex-
pression and ANXA1 knockdown result in similar onco-
genic phenotypes (25). Finally, miR-100 has recently been
shown to modulate expression of apoptotic genes as well. In
a colorectal cancer cell line, expression of p53 and caspase-
3 (both pro-apoptotic) was increased by miR-100, while the
expression of Bcl-2 and NF-jB (both anti-apoptotic) was
decreased. Upregulation of miR-100 therefore sensitized
cells to radiation (55). In addition to involvement in
numerous important processes such as immune and
inflammatory response, the transcription factor NF-jB is
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also known as crucial early response gene responsible for
modulating cellular response and apoptosis in response to
injury (68). Interestingly, the activated NF-jB pathway is
linked to radioresistance, and suppression of this pathway
might offer another opportunity to overcome radioresistance
(69). Expression of miR-9 has been show to correlate
negatively with NF-jB expression in irradiated lung cancer
cells and overexpression of miR-9 results in decreased NF-
jB levels, leading in turn to increased sensitivity towards
radiotherapy (70). Similar effects have been demonstrated
for let-7g, suggesting that both miRNAs regulate response
to radiation through inhibition of NF-jB (70).
CONCLUSION
Recently reported research provides limited but promising
data pertinent to miRNAs and their impact on radiotherapy
for cancer. miRNAs offer potential as new biomarkers to
inform decisions in a clinical setting. miRNAs might be
used not only to predict and monitor radiotherapy
responses, but to modulate radiotherapy response as well.
Mechanisms of action by which miRNAs affect radiation
sensitivity include modulation of DNA damage response
and regulation of cellular signaling pathways such as
oncogene, tumor suppressor genes or apoptosis. miRNAs
hold significant potential as diagnostic, prognostic and
therapeutic targets for use in the near future. More studies
are needed to further demonstrate the potential expanded
role of radiotherapy in targeted molecular-based diagnostics
and cancer treatment.
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